Silexion Therapeutics Ltd. (SLXN) Options Greeks

Options Greeks measure sensitivity to various factors: Delta (price), Gamma (delta change), Theta (time decay), and Vega (volatility). They are essential for risk management and position sizing.

Silexion Therapeutics Ltd. (SLXN) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $280,482, listed on NASDAQ, employing roughly 11 people, carrying a beta of -0.29 to the broader market. Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. Led by Ilan Hadar, public since 2024-08-16.

Options Greeks analysis provides sensitivity measures for price, time, and volatility. No recent options activity for SLXN as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how options Greeks is reported and how to read the data →